dexpramipexole dexpramipexole dexpramipexole (kns-760704) is an orally administered drug candidate shown to selectively and significantly lower eosinophil counts in human blood and tissue. the drug is currently in clinical development for eosinophil-associated diseases by knopp biosciences llc. dexpramipexole names preferred iupac name (6r)-n6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine identifiers cas number 104632-28-2 y104632-27-1 (dihydrochloride) y 3d model (jsmol) interactive image chembl chembl249420 n chemspider 54002 n kegg d09886 pubchem cid 59868 unii wi638gus96 yi9038pko43 (dihydrochloride) y comptox dashboard (epa) dtxsid50146624 inchi inchi=1s/c10h17n3s/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12h,2-6h2,1h3,(h2,11,13)/t7-/m1/s1 nkey: fasdkyopvnhblu-ssdottswsa-n ninchi=1/c10h17n3s/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12h,2-6h2,1h3,(h2,11,13)/t7-/m1/s1key: fasdkyopvnhblu-ssdottswbr smiles cccn1ccc(n=c(n)s2)=c2c1 properties chemical formula c10h17n3s molar mass 211.33 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references in a phase 2 clinical trial (as201), dexpramipexole significantly lowered eosinophil counts and improved lung function in subjects with moderate-to-severe eosinophilic asthma. previous clinical trials showed that dexpramipexole significantly reduced eosinophil counts and glucocorticoid requirements in patients with hypereosinophilic syndrome (hes) and significantly reduced blood and tissue eosinophil counts in patients with chronic rhinosinusitis with nasal polyps. the sponsor is continuing development of dexpramipexole in eosinophilic asthma, hes, and eosinophilic gastrointestinal diseases. the drug was originally investigated by knopp biosciences and biogen idec for the treatment of amyotrophic lateral sclerosis (als), also known as lou gehrig’s disease. a 2010 phase ii clinical trial showed a slowing of als disease progression and mortality benefits. in january 2013, biogen idec announced it was discontinuing its development of dexpramipexole in als due to lack of efficacy in a phase iii study. dexpramipexole is the enantiomer of pramipexole. it is a low molecular weight, orally bioavailable, water-soluble small molecule with linear pharmacokinetics. dexpramipexole was originally identified as a candidate therapy for als by james bennett, m.d., ph.d., then of the university of virginia.